Royalty Pharma Plc Cl A (RPRX)
33.00 x 100 33.85 x 2
Post-market by (Cboe BZX)
33.70 +0.20 (+0.60%) 03/21/25 [NASDAQ]
33.00 x 100 33.85 x 2
Post-market 33.85 +0.15 (+0.45%) 19:29 ET
for Fri, Mar 21st, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Sales | 2,263,576 | 2,354,554 | 2,237,215 | 2,289,463 | 2,122,353 |
Gross Profit | 2,263,576 | 2,354,554 | 2,237,215 | 2,289,463 | 2,122,353 |
Operating Expenses | 971,132 | 862,404 | 1,930,150 | 858,748 | 526,954 |
Operating Income | 1,292,444 | 1,492,150 | 307,065 | 1,430,715 | 1,595,399 |
Interest Expense | 225,512 | 187,187 | 187,961 | 166,142 | 157,059 |
Other Income | 263,881 | 395,125 | 110,960 | -23,372 | 263,614 |
Pre-tax Income | 1,330,813 | 1,700,088 | 230,064 | 1,241,201 | 1,701,954 |
Net Income Continuous | 1,330,813 | 1,700,088 | 230,064 | 1,241,201 | 1,701,954 |
Minority Interests | 471,830 | 565,254 | 187,232 | 621,473 | 726,914 |
Net Income | $858,983 | $1,134,834 | $42,832 | $619,728 | $975,040 |
EPS Basic Total Ops | 1.92 | 2.54 | 0.10 | 1.49 | 1.32 |
EPS Basic Continuous Ops | 2.97 | 3.80 | 0.53 | 2.99 | 4.53 |
EPS Diluted Total Ops | 1.91 | 2.53 | 0.10 | 1.49 | 1.32 |
EPS Diluted Continuous Ops | 2.24 | 2.82 | 0.53 | 2.99 | 4.53 |
EPS Diluted Before Non-Recurring Items | 4.13 | 4.49 | 3.68 | 2.91 | 1.61 |
EBITDA(a) | $1,312,006 | $1,512,649 | $334,091 | $1,473,873 | $1,630,172 |